Published on 30 May 2023 on Simply Wall St. via Yahoo Finance
Veracyte, Inc.'s (NASDAQ:VCYT) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 6x Veracyte, Inc. (NASDAQ:VCYT) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in the United States have P/S ratios greater than 13.2x and even P/S higher than 57x are not unusual. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so limited.
View our latest analysis for Veracyte
